GlassScriptPhysician profile
Samera Majeed
NPI 1578959193
$959.45
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $201 · 2021: $18.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243.80 | 2019-2020 | |
| Pfizer INC. | $157.89 | 2019-2020 | |
| Lilly USA, LLC | $115.68 | 2019-2020 | |
| Amgen INC. | $73.32 | 2019-2020 | |
| Medtronic Vascular, INC. | $72.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $62.72 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.58 | 2019 | |
| Glaxosmithkline, LLC. | $38.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.43 | 2019 | |
| Abbvie INC. | $18.46 | 2021 | |
| Sanofi Pasteur INC. | $17.55 | 2019 | |
| Astellas Pharma US INC | $17.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samera Majeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.